Shares in CB2 Insights Inc. (CSE:CBII, OTCQB: FRLF,Forum) spiked on Monday morning, following the announcement that the Company will begin a prospective trial with GL Brands (OTCQB: FRLF) to assess the safety, efficacy and other health measures for patients using cannabidiol (CBD) soft gel capsules to treat anxiety.
For more on this trial, click here.
Last week, the medical cannabis Company stated that it had primed its core technology platform, Scalefor streamlining and aggregating disparate healthcare data systems to enable current and future partners to make faster and smarter business decisions.
FULL DISCLOSURE: CB2 Insights Inc. is a client of Stockhouse Publishing.